Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Drugs that could transform the lives of some Cystic Fibrosis sufferers should not be available on the Welsh NHS, Welsh government advisers say.
Kalydeco is authorised in England, Scotland and Northern Ireland but it has not been recommended in Wales because of its cost.
Health Minister Mark Drakeford will now take the final decision on the drug.
The Cystic Fibrosis Trust has warned that patients in Wales could be faced with a second class health service.
The life-threatening genetic disorder damages the lungs and digestive system.
Kalydeco is said to be the first drug to treat the root cause of cystic fibrosis for people with the G551D mutation and could dramatically improve the life expectancy of sufferers.
http://www.bbc.co.uk/news/uk-wales-22440811
Kalydeco is authorised in England, Scotland and Northern Ireland but it has not been recommended in Wales because of its cost.
Health Minister Mark Drakeford will now take the final decision on the drug.
The Cystic Fibrosis Trust has warned that patients in Wales could be faced with a second class health service.
The life-threatening genetic disorder damages the lungs and digestive system.
Kalydeco is said to be the first drug to treat the root cause of cystic fibrosis for people with the G551D mutation and could dramatically improve the life expectancy of sufferers.
http://www.bbc.co.uk/news/uk-wales-22440811